Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10051	Companies
205071	Keywords
135295	Articles
108715	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 08/01/2025 at 13:00, 7 months 17 days ago

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Moderna reports Q2 revenue of $0.1B, net loss of $(0.8)B, updates 2025 revenue to $1.5-$2.2B due to shipment timing, improves operating expenses by $400M, reiterates $6B year-end cash balance. FDA approvals for flu vaccine

Revenue Moderna Q2 2025 FDA Approvals
BRIEF

published on 08/01/2025 at 12:05, 7 months 17 days ago

UK Court Confirms Validity of Moderna's EP'949 Patent

Patent MRNA Technology Moderna Pfizer/BioNTech UK Court
PRESS RELEASE

published on 08/01/2025 at 12:00, 7 months 17 days ago

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Moderna's EP'949 patent validity upheld by UK Court of Appeal in Pfizer/BioNTech case. Recent legal developments in Europe further strengthen Moderna's intellectual property portfolio

MRNA Technology Moderna Pfizer/BioNTech EP'949 Patent UK Court Of Appeal
BRIEF

published on 07/30/2025 at 22:10, 7 months 18 days ago

Moderna Gains European Approval for New COVID-19 Vaccine

COVID-19 Vaccine European Commission Moderna SARS-CoV-2 SPIKEVAX®
PRESS RELEASE

published on 07/30/2025 at 22:05, 7 months 18 days ago

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna receives marketing authorization from the European Commission for updated COVID-19 vaccine Spikevax® targeting SARS-CoV-2 variant LP.8.1

COVID-19 Vaccine European Commission Moderna Spikevax LP.8.1
BRIEF

published on 07/28/2025 at 13:05, 7 months 21 days ago

Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025

MRNA Therapeutics Moderna Melanoma Bladder Cancer ESMO Congress 2025
PRESS RELEASE

published on 07/28/2025 at 13:00, 7 months 21 days ago

Moderna Announces Data to be Presented at ESMO Congress 2025
Moderna to present abstracts on investigational mRNA therapeutics at 2025 ESMO Congress. Mini oral presentation on mRNA-4359 and two poster presentations on intismeran autogene

Cancer Therapy MRNA Therapeutics Moderna ESMO Congress T-cell Immune Responses
BRIEF

published on 07/25/2025 at 14:50, 7 months 24 days ago

EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization

COVID-19 Vaccine European Commission Moderna EMA Approval SARS-CoV-2 LP.8.1
PRESS RELEASE

published on 07/25/2025 at 14:45, 7 months 24 days ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine targeting variant LP.8.1 receives positive CHMP opinion for EU marketing authorization. European Commission to decide for 2025-2026 season

COVID-19 Vaccine European Commission Moderna CHMP LP.8.1
BRIEF

published on 06/30/2025 at 13:05, 8 months 18 days ago

Moderna Reports Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna Influenza Vaccine Phase 3 Results RVE MRNA-1010

Accesswire

Published on 03/18/2026 at 18:10, 23 minutes ago

Silver X Mining Closes C$69M Brokered Private Placement of Secured Convertible Debentures
Published on 03/18/2026 at 14:30, 4 hours 3 minutes ago

Ground Geophysics Underway at Murphy Lake, 5 km From Isoenergy's Hurricane Deposit, Athabasca Basin
Published on 03/18/2026 at 14:15, 4 hours 18 minutes ago

Apex Provides Phase I Drilling Update at the Rift Rare Earth Project in Nebraska, U.S.A.
Published on 03/18/2026 at 14:00, 4 hours 33 minutes ago

Route1 Announces Filing of Parking Copilot Patent Application and Confirms Expected Launch Date for "Mr. Parking"
Published on 03/18/2026 at 14:00, 4 hours 33 minutes ago

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

View all ACCESSWIRE

EQS Group

Published on 03/18/2026 at 18:27, 6 minutes ago

POS-Transaction in Own Shares
Published on 03/18/2026 at 18:15, 18 minutes ago

Northern Data Group releases audited FY 2025 Financial Results
Published on 03/18/2026 at 17:43, 50 minutes ago

Voluntary public takeover bid by B&C Holding Österreich GmbH for Semperit Aktiengesellschaft Holding
Published on 03/18/2026 at 17:34, 59 minutes ago

Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 03/18/2026 at 17:32, 1 hour 1 minute ago

ams OSRAM unveils ultra‑efficient microLED array for slow-and-wide AI optical interconnects and advances to product development

Les Echos

Published on 03/18/2026 at 18:00, 33 minutes ago

Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 48 minutes ago

Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
Published on 03/18/2026 at 17:40, 53 minutes ago

260318 BENETEAU Presentation FY 2025
Published on 03/18/2026 at 17:40, 53 minutes ago

260318 BENETEAU FY 2025 Results
Published on 03/18/2026 at 07:00, 11 hours 33 minutes ago

Mersen: A resilient performance in 2025, return to growth expected in 2026

View all LES ECHOS COMFI WIRE